Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic and Pharmacologic Inhibition of mTORC1 Promotes EMT by a TGF-β–Independent Mechanism

28 Sept 2013

Abstract excerpt

Epithelial-to-mesenchymal transition (EMT) is a transdifferentiation process that converts epithelial cells into highly motile mesenchymal cells. This physiologic process occurs largely during embryonic development but is aberrantly reactivated in different pathologic situations, including fibrosis and cancer. We conducted a siRNA screening targeted to the human kinome with the aim of discovering new EMT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer Diagnosis and Treatment
Share to Metastasis and carcinoma case studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24078802
DOI: 10.1158/0008-5472.can-13-0560

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic and Pharmacologic Inhibition of mTORC1 Promotes EMT by a TGF-β–Independent MechanismPMID 24078802Read ↗

Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cellsSemantic proximity Read ↗

Active mTOR in Lung Epithelium Promotes Epithelial-Mesenchymal Transition and Enhances Lung Fibrosis.Semantic proximity Read ↗

The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.Semantic proximity Read ↗

mTOR Signaling in Metabolism and CancerSemantic proximity Read ↗

mTOR: Role in cancer, metastasis and drug resistanceSemantic proximity Read ↗

ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancerSemantic proximity Read ↗

LKB1 as a Tumor Suppressor in Uterine Cancer: Mouse Models and Translational Studies.Semantic proximity Read ↗

Review: Mammalian Target of Rapamycin (mTOR) Pathway Is Critical in Developing Most Renal Cell Tumors.Semantic proximity Read ↗

An expanding role for mTOR in cancer.Semantic proximity Read ↗

The LKB1 tumor suppressor negatively regulates mTOR signalingSemantic proximity Read ↗

Blocking the mTOR pathway: a drug discovery perspectiveSemantic proximity Read ↗

Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.